Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28828309 | 0.76 | CHUK (0.43) | CYP11B1CYP11B2ALDH1A1MCL1ESR2 | |
| SCHEMBL12326417 | 0.73 | PDE9A (0.49) | PDE9AKDM1AALDH1A1ARESR2 | |
| SCHEMBL30985 | 0.73 | TRPV4 (0.57) | CYP11B1CYP11B2AR | |
| SCHEMBL12326411 | 0.72 | CYP11B1 (0.55) | CYP11B1CYP11B2KDM1A | |
| SCHEMBL16604315 | 0.72 | CYP11B1 (0.55) | CYP11B1CYP11B2KDM1A | |
| SCHEMBL9040621 | 0.72 | MAOA (0.47) | PDE9ACYP11B1CYP11B2ALDH1A1CYP2A6 | |
| SCHEMBL91880 | 0.71 | ALDH1A1 (0.52) | PDE9ACYP11B2KDM1AALDH1A1CYP2A6 | |
| SCHEMBL20257179 | 0.71 | PDE9A (0.47) | PDE9ACYP11B1CYP11B2KDM1AESR1 | |
| SCHEMBL16604328 | 0.71 | CYP11B1 (0.50) | PDE9ACYP11B1CYP11B2KDM1A | |
| SCHEMBL19608729 | 0.70 | ALDH1A1 (0.50) | PDE9ACYP11B2KDM1AALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-07-04 | — | — | US | disclosed |
| EP-4313971-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157289-A | Substituted pyrrolecarboxamides, process for their preparation and their use as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022207404-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDC7, CDK7, CDK17 | PDE9A 1506/4885CYP11B1 3222/4885CYP11B2 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.